Shares of bluebird bio (BLUE) are currently down nearly 8% on Wednesday morning. The clinical-stage biotech reported a mixed result for the fourth quarter, as earnings missed estimates, while revenues surpassed expectations.
from RTT - Earnings https://ift.tt/2V0wSgi
via IFTTT
No comments:
Post a Comment